Multiple Sclerosis Therapeutics Market Forecasted to Reach USD 66.80 Billion by 2035 Driven by AI-Enabled Care, Biologic Innovations, and Rising Demand for Disease-Modifying Therapies

According to Precedence Research, the global multiple sclerosis therapeutics market size surpassed USD 34.80 billion in 2025 and is projected to rise from USD 37.16 billion in 2026 to approximately USD 66.80 billion by 2035, expanding at a CAGR of 6.90% from 2026 to 2035.

The growing burden of neurological autoimmune disorders, rising awareness regarding early diagnosis, and rapid adoption of disease-modifying therapies are fueling demand across major healthcare economies. Increasing investments in monoclonal antibodies, oral disease-modifying drugs, and advanced immunotherapies are significantly improving relapse management and long-term neurological outcomes for patients suffering from multiple sclerosis (MS).

The industry is also witnessing a strong transition toward patient-centric treatment approaches, remote monitoring solutions, and personalized therapeutic pathways, creating new opportunities for pharmaceutical companies, healthcare providers, and biotechnology innovators.

Where Data Meets Strategic Clarity 📥 View Sample Pages of the Complete Report 👉https://www.precedenceresearch.com/sample/8432

Multiple Sclerosis Therapeutics Market Size and Forecast

🔹 Market size in 2025: USD 34.80 Billion
🔹 Market size in 2026: USD 37.16 Billion
🔹 Market size by 2035: USD 66.80 Billion
🔹 CAGR: 6.90% (2026-2035)
🔹 Forecast period: 2026-2035
🔹 Base year: 2025

Why is the Multiple Sclerosis Therapeutics Market Growing Rapidly?

The global rise in multiple sclerosis prevalence is creating urgent demand for more effective and long-term disease management solutions. Improvements in MRI imaging, biomarker identification, and neurological diagnostics are enabling earlier disease detection, which is increasing patient access to disease-modifying therapies.

Another major growth catalyst is the shift toward high-efficacy biologics and targeted monoclonal antibodies. These therapies offer stronger relapse prevention, reduced disease progression, and improved neurological outcomes compared to traditional treatment options.

Healthcare systems are also focusing heavily on personalized medicine. As physicians increasingly tailor treatment plans based on patient-specific disease progression, genetic markers, and relapse risk profiles, pharmaceutical companies are accelerating investments in next-generation MS therapeutics.

How Artificial Intelligence Revolutionizes Multiple Sclerosis Treatment?

Artificial intelligence is rapidly becoming one of the most disruptive technologies in the multiple sclerosis therapeutics industry. AI-powered MRI interpretation systems are helping neurologists identify lesions and disease progression earlier and more accurately than traditional imaging assessment methods. This enables faster diagnosis and more precise treatment planning.

AI is also transforming pharmaceutical R&D operations. Drug developers are increasingly utilizing machine learning algorithms to identify promising therapeutic targets, predict patient responses, optimize clinical trials, and accelerate disease-modifying drug development timelines. Predictive analytics and AI-driven relapse forecasting tools are expected to become essential components of future MS care ecosystems.

🔗 What's Fueling the Next Wave of Growth? 👉https://www.precedenceresearch.com/multiple-sclerosis-therapeutics-market

Multiple Sclerosis Therapeutics Market Key Growth Drivers

🔹Increasing Prevalence of Multiple Sclerosis Worldwide: The rising number of diagnosed MS cases globally is one of the primary factors driving market expansion. Improved disease awareness, earlier diagnosis, and stronger neurologist networks are increasing demand for innovative therapeutic solutions.

🔹Growing Adoption of Monoclonal Antibodies: Monoclonal antibody therapies continue to gain traction because of their superior efficacy in reducing relapse frequency and slowing neurological disability progression. High clinical effectiveness is encouraging broader physician adoption worldwide.

🔹Advancements in Disease-Modifying Therapies: Continuous innovations in biologics, targeted therapies, and neuroprotective treatments are significantly improving disease management. Pharmaceutical companies are increasingly focused on developing next-generation therapies with enhanced safety and efficacy profiles.

Emerging Opportunities in the Multiple Sclerosis Therapeutics Market

🔹AI-Driven Healthcare and Digital Neurology: The integration of AI, digital health platforms, and remote patient monitoring technologies presents significant long-term growth opportunities. AI-powered analytics can improve relapse prediction, optimize treatment pathways, and enhance patient engagement.

🔹Expansion of Home-Based MS Care: The growing adoption of telehealth services, self-administered therapies, and homecare treatment models is creating new growth avenues in chronic disease management.

🔹Growth Opportunities in Emerging Markets: Countries across Asia-Pacific, Latin America, and the Middle East are rapidly improving healthcare infrastructure and increasing investment in neurology care, creating substantial untapped market potential.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Multiple Sclerosis Therapeutics Market Trends

🔸Rising Adoption of High-Efficacy Oral Therapies: The growing preference for oral disease-modifying therapies is transforming treatment approaches in multiple sclerosis care. Oral drugs such as fingolimod and dimethyl fumarate are gaining widespread adoption due to improved convenience, enhanced treatment adherence, and reduced hospital dependency.

Patients increasingly prefer therapies that can be self-administered at home, minimizing frequent hospital visits while improving long-term disease management.

🔸Artificial Intelligence Revolutionizing MS Diagnosis and Treatment: Artificial intelligence is becoming a critical component of the multiple sclerosis therapeutics ecosystem. AI-powered MRI analytics, predictive relapse modeling, and personalized treatment planning are helping neurologists detect disease progression earlier and optimize patient outcomes.

Pharmaceutical and biotechnology companies are also leveraging AI to accelerate drug discovery, identify novel therapeutic targets, and streamline clinical trial development.

🔸Growing Demand for Personalized Medicine: Advancements in biomarker research, genomic profiling, and precision neurology are enabling more personalized treatment strategies tailored to individual disease progression patterns. Personalized medicine is expected to become one of the most influential trends in the future MS treatment landscape.

🔸Expansion of Biosimilars Enhancing Treatment Accessibility: The launch of biosimilar therapies, including natalizumab biosimilars, is improving treatment affordability in cost-sensitive regions. Biosimilars are expanding patient access to advanced therapies while helping healthcare systems reduce long-term treatment costs.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉https://www.precedenceresearch.com/checkout/8432

Multiple Sclerosis Therapeutics Market Regional Outlook

North America accounted for 42% of the global market share in 2025 and continues to lead the industry due to strong healthcare infrastructure, rapid FDA approvals, advanced neurological care systems, and widespread adoption of biologics and monoclonal antibodies.

The United States remains the largest contributor to regional growth because of extensive clinical trial activity, favorable reimbursement policies, and growing use of high-efficacy disease-modifying therapies.

Asia-Pacific is projected to expand at the fastest CAGR of 10.8% during the forecast period. Rising healthcare expenditure, growing awareness about neurological diseases, and increasing access to advanced therapies are fueling regional growth.

China and India are witnessing significant improvements in diagnostic capabilities, specialty neurology care, and participation in global clinical trials.

Europe continues to show stable growth supported by favorable government healthcare initiatives, increasing awareness about MS, and strong adoption of disease-modifying therapies across Germany, France, Italy, and the United Kingdom.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy - Get the Sample Report@https://www.precedenceresearch.com/sample/8432

Multiple Sclerosis Therapeutics Market Segmental Outlook

🔸Drug Class Insights

The monoclonal antibodies segment dominated the multiple sclerosis therapeutics market by capturing 32% of the market share in 2025. The segment generated around USD 11.14 billion in revenue and is projected to reach nearly USD 26.72 billion by 2035, expanding at the fastest CAGR of 10.5% during the forecast period. Growth is mainly driven by the superior efficacy of monoclonal antibodies in reducing relapse rates and slowing disability progression. Rising patient preference for long-term effective therapies and improved clinical outcomes are further supporting segment expansion.

The immunomodulators segment accounted for 24% of the market share in 2025, reaching approximately USD 8.35 billion. The segment is expected to grow to nearly USD 12.02 billion by 2035 at a CAGR of 3.8%. The widespread use of immunomodulators in treating relapsing MS, physician familiarity, and availability of generic drugs continue to support market growth. These therapies remain highly preferred in developing regions due to affordability and long-term disease management benefits.

The immunosuppressants segment generated around USD 4.87 billion in 2025 and is projected to reach nearly USD 8.02 billion by 2035, growing at a CAGR of 4.5%. Increasing adoption of immune-targeting therapies and combination treatments is driving demand. These therapies help reduce neurological damage and suppress overactive immune responses, making them important in specialty neurology care.

The corticosteroids segment accounted for USD 3.48 billion in 2025 and is projected to reach nearly USD 5.34 billion by 2035 at a CAGR of 3%. Corticosteroids held 10% of the market share in 2025 due to their rapid effectiveness in controlling MS flare-ups and reducing inflammation. However, increasing preference for long-term disease-modifying therapies is limiting faster growth.

🔸Disease Type Insights

The relapsing-remitting multiple sclerosis (RRMS) segment held the largest market share of 64% in 2025. The segment generated approximately USD 22.27 billion and is projected to reach nearly USD 40.08 billion by 2035, growing at a CAGR of 6.5%. RRMS remains the most commonly diagnosed form of MS, supported by early diagnosis rates and broad availability of effective therapies, including biologics and oral medications.

The secondary progressive multiple sclerosis (SPMS) segment captured 18% of the market share in 2025. It generated around USD 6.26 billion and is expected to reach USD 13.36 billion by 2035 at a CAGR of 8.2%. Rising focus on slowing disease progression and advancements in targeted drug therapies are fueling growth in this segment.

The primary progressive multiple sclerosis (PPMS) segment accounted for 14% of the market share in 2025 and is anticipated to witness the fastest CAGR of 9.5% through 2035. The segment generated USD 4.87 billion in 2025 and is projected to reach nearly USD 10.69 billion by 2035. Growing clinical research and development of disease-modifying therapies are improving treatment prospects for PPMS patients.

The progressive-relapsing multiple sclerosis (PRMS) segment represented 4% of the market share in 2025. It generated approximately USD 1.39 billion and is projected to reach nearly USD 2.67 billion by 2035, growing at a CAGR of 5.5%. Improved biomarker technologies and increased neurological research are supporting early diagnosis and treatment advancements for this rare MS type.

🔸Route of Administration Insights

The oral segment dominated the market with a 44% share in 2025. The segment generated around USD 15.31 billion and is projected to reach nearly USD 33.40 billion by 2035, expanding at a CAGR of 9.2%. Growing patient preference for convenient oral medications and improved treatment adherence are major factors driving segment growth.

The injectable segment accounted for 30% of the market share in 2025, generating approximately USD 10.44 billion. The segment is expected to reach nearly USD 14.70 billion by 2035 at a CAGR of 3.5%. Injectable therapies continue to be widely used due to their long clinical history and established safety profile.

The intravenous (IV) infusion segment generated around USD 9.05 billion in 2025 and is projected to reach nearly USD 18.70 billion by 2035, growing at a CAGR of 8.8%. Increasing adoption of high-efficacy biologics and monoclonal antibodies is boosting demand for infusion-based therapies, especially for moderate to severe MS cases.

🔸Distribution Channel Insights

Hospital pharmacies held the largest market share of 46% in 2025. The segment generated approximately USD 16.01 billion and is projected to reach nearly USD 28.06 billion by 2035 at a CAGR of 5.8%. Growing demand for biologics and infusion therapies in supervised healthcare settings continues to support segment growth.

The retail pharmacies segment accounted for 38% of the market share in 2025 and generated around USD 13.22 billion. The segment is expected to reach nearly USD 24.05 billion by 2035 at a CAGR of 6.2%. Convenience in prescription refills and increasing availability of oral MS medications are driving growth.

The online pharmacies segment generated approximately USD 5.57 billion in 2025 and is projected to reach nearly USD 14.70 billion by 2035, expanding at the fastest CAGR of 11.8%. Rising adoption of telemedicine, digital healthcare platforms, and home delivery services is accelerating growth in online pharmacy channels.

🔸End-Use Insights

The hospitals segment dominated the market with a 40% share in 2025. The segment generated approximately USD 13.92 billion and is projected to reach nearly USD 23.38 billion by 2035 at a CAGR of 5.5%. Hospitals remain the primary centers for diagnosis, relapse management, infusion therapy, and multidisciplinary MS care.

The specialty neurology clinics segment accounted for 30% of the market share in 2025. The segment generated around USD 10.44 billion and is projected to reach nearly USD 22.71 billion by 2035, growing at a CAGR of 8.8%. Increasing adoption of personalized neurological care and precision treatment approaches is fueling segment growth.

The homecare settings segment generated approximately USD 6.26 billion in 2025 and is expected to reach nearly USD 14.70 billion by 2035 at the fastest CAGR of 10.5%. Growing use of oral and self-administered therapies, along with advancements in telehealth and remote patient monitoring, are supporting the expansion of home-based MS care.

The rehabilitation centers segment accounted for USD 4.18 billion in 2025 and is projected to reach nearly USD 6.01 billion by 2035, growing at a CAGR of 4.2%. Rising emphasis on mobility improvement, physiotherapy, and long-term neurological rehabilitation continues to support demand for rehabilitation services.

✚ Related Topics You May Find Useful:

➡️ Multiple Sclerosis Diagnostics Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/multiple-sclerosis-diagnostics-market

➡️ Multiple Sclerosis Drugs Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/multiple-sclerosis-drugs-market

➡️ U.S. Multiple Sclerosis Drugs Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/us-multiple-sclerosis-drugs-market

➡️ Clinical Trials Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/clinical-trials-market

➡️ Central Nervous System Therapeutics Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/central-nervous-system-therapeutic-market

➡️ Neurology Market Size, Share and Trends 2026 to 2035 👉 https://www.precedenceresearch.com/neurology-market

Multiple Sclerosis Therapeutics Market Key Players

➢Biogen Inc.: Biogen Inc. offers a strong portfolio of multiple sclerosis therapeutics including TYSABRI (natalizumab), TECFIDERA (dimethyl fumarate), VUMERITY, AVONEX, and PLEGRIDY, primarily targeting relapsing forms of multiple sclerosis.

➢Novartis AG: Novartis AG provides multiple sclerosis therapies such as GILENYA (fingolimod), MAYZENT (siponimod), and Kesimpta (ofatumumab) for the treatment of relapsing multiple sclerosis.

➢F. Hoffmann-La Roche Ltd.: F. Hoffmann-La Roche Ltd. offers OCREVUS (ocrelizumab) and Ocrevus Zunovo, which are used for the treatment of relapsing as well as primary progressive multiple sclerosis.

➢Sanofi S.A.: Sanofi S.A. provides multiple sclerosis therapies including AUBAGIO (teriflunomide) and LEMTRADA (alemtuzumab), along with pipeline candidates such as tolebrutinib for progressive MS.

➢Merck KGaA: Merck KGaA offers MS therapeutics such as MAVENCLAD (cladribine) and REBIF (interferon beta-1a), mainly focused on relapsing forms of multiple sclerosis.

➢Bristol Myers Squibb: Bristol Myers Squibb provides ZEPOSIA (ozanimod) for relapsing multiple sclerosis and strengthened its MS portfolio through the acquisition of Celgene Corporation.

➢Johnson & Johnson: Johnson & Johnson, through its Janssen Pharmaceuticals division, offers PONVORY (ponesimod) for the treatment of relapsing multiple sclerosis.

➢Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is known for COPAXONE (glatiramer acetate) and several generic therapies used in the treatment of relapsing-remitting multiple sclerosis.

➢Pfizer Inc.: Pfizer Inc. participates in the multiple sclerosis therapeutics market through neurology and immunology research collaborations and drug development initiatives.

➢TG Therapeutics: TG Therapeutics offers BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for the treatment of relapsing multiple sclerosis.

➢EMD Serono: EMD Serono markets REBIF and MAVENCLAD in North America as part of the multiple sclerosis portfolio of Merck KGaA.

➢UCB Pharma: UCB Pharma is involved in neurological and immunological research programs with a focus on developing therapies for autoimmune disorders, including multiple sclerosis.

➢Bayer AG: Bayer AG offers BETASERON/Betaferon (interferon beta-1b), which is widely used for the treatment of relapsing-remitting multiple sclerosis.

➢Celgene Corporation: Celgene Corporation developed OZANIMOD, which was later commercialized as ZEPOSIA under Bristol Myers Squibb for relapsing multiple sclerosis treatment.

➢Mitsubishi Tanabe Pharma: Mitsubishi Tanabe Pharma participates in the multiple sclerosis therapeutics market through specialty neurology therapies and investigational treatment programs.

Latest Industry Developments

➢In February 2026, TG Therapeutics presented new clinical data at the ACTRIMS meeting in San Diego, reinforcing the therapeutic efficacy of its MS treatment portfolio.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.

📥 Instant Report Delivery Available | 💳 Buy Now 👉 https://www.precedenceresearch.com/checkout/8432

Segment Covered in the Report

🔸By Drug Class

Immunomodulators
Interferons
Glatiramer Acetate
Immunosuppressants
Monoclonal Antibodies
Corticosteroids
Sphingosine-1-Phosphate (S1P) Receptor Modulators
Others

🔸By Disease Type

Relapsing-Remitting Multiple Sclerosis (RRMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Primary Progressive Multiple Sclerosis (PPMS)
Progressive-Relapsing Multiple Sclerosis (PRMS)

🔸By Route of Administration

Oral
Injectable
Intravenous (IV) Infusion

🔸By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

🔸By End-use

Hospitals
Specialty Neurology Clinics
Homecare Settings
Rehabilitation Centers

🔸By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.